HR Execs on the Move

Zitter

www.zitter.com

 
Zitter Health Insights is a market-leading business intelligence firm serving life science companies, specialty pharmacies and managed healthcare organizations focused on optimizing patient access to pharmaceuticals. The company offers the nation`s largest payer research panel and the largest database of prior authorization policies. The average panel member represents 1 million+ covered lives and the research portfolio covers the entire spectrum of payer-influenced entities. Insights are generated primarily in multi-client subscription formats including: Managed Care Oncology Index, Managed Care Biologics and Injectables Index, Managed Care Benefit Design Index, Prior Authorization Tracking Tool, Managed Care Message Monitor, Co-Pay Offset Monitor, and P&T ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.zitter.com
  • 290 W. Mt. Pleasant Avenue Suite # 2210
    Livingston, NJ USA 07039
  • Phone: 973.376.1300

Executives

Name Title Contact Details

Similar Companies

Stockamp and Associates

Stockamp delivers: Stockamp helps high-performing hospitals reach the pinnacle of financial and operational excellence. We invented and perfected the science of revenue cycle management for hospitals and health systems, based on our unmatched

Health Access Washoe County

Health Access Washoe County is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Third Pole

Third Pole, Inc. is a US-based company developing next generation life-saving cardiopulmonary therapies. We are building on our team`s legacy in inhaled nitric oxide (NO), the current standard of care, to develop next generation life-saving heart and lung therapies.

That Touch Of Class

That Touch Of Class is a Caro, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.